Octreotide
- PDF / 169,419 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 9 Downloads / 120 Views
1 S
Lack of efficacy: case report In a retrospective analysis of 30 patients submitted to endoscopic endonasal removal of pituitary adenomas between January 2005 and September 2008, one patient [age and sex not stated] was described, who exhibited lack of efficacy during treatment with octreotide for growth hormone (GH)-secreting pituitary adenoma. The patient, who had GH-secreting pituitary adenoma, was scheduled to undergo endoscopic endonasal resection. The patient was operated on unspecified general anaesthesia and orotracheal intubation, in supine position with the head fixed in a standard 3-pin-holder, slightly flexed and turned 10 degrees toward the surgeon. Ceftriaxone and clindamycin were administered 30 minutes prior to the surgery and kept 3 days following surgery. Both nostrils were washed using a topical vasoconstrictor. The cavernous sinus invasion was sub totally removed, and therapy with octreotide [route and dosage not stated] was initiated. However, the patient was submitted to radiosurgery owing to lack of control with octreotide. dos Santos ARL, et al. Endoscopic endonasal transsphenoidal approach for pituitary adenomas: Technical aspects and report of casuistic. Arquivos de Neuro-Psiquiatria 68: 803499663 608-612, No. 4, Aug 2010. Available from: URL: http://doi.org/10.1590/s0004-282x2010000400024
0114-9954/20/1820-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 5 Sep 2020 No. 1820
Data Loading...
